These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32710493)

  • 1. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.
    Mease PJ; Gladman DD; Gomez-Reino JJ; Hall S; Kavanaugh A; Lespessailles E; Schett G; Paris M; Delev N; Teng L; Wollenhaupt J
    ACR Open Rheumatol; 2020 Aug; 2(8):459-470. PubMed ID: 32710493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Crowley J; Thaçi D; Joly P; Peris K; Papp KA; Goncalves J; Day RM; Chen R; Shah K; Ferrándiz C; Cather JC
    J Am Acad Dermatol; 2017 Aug; 77(2):310-317.e1. PubMed ID: 28416342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
    Schett G; Wollenhaupt J; Papp K; Joos R; Rodrigues JF; Vessey AR; Hu C; Stevens R; de Vlam KL
    Arthritis Rheum; 2012 Oct; 64(10):3156-67. PubMed ID: 22806399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.
    Deodhar AA; Combe B; Accioly AP; Bolce R; Zhu D; Gellett AM; Sprabery AT; Burmester GR
    Ann Rheum Dis; 2022 Jul; 81(7):944-950. PubMed ID: 35393269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome.
    Mease PJ; Hatemi G; Paris M; Cheng S; Maes P; Zhang W; Shi R; Flower A; Picard H; Stein Gold L
    Am J Clin Dermatol; 2023 Sep; 24(5):809-820. PubMed ID: 37316690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.
    Wells AF; Edwards CJ; Kivitz AJ; Bird P; Nguyen D; Paris M; Teng L; Aelion JA
    Rheumatology (Oxford); 2018 Jul; 57(7):1253-1263. PubMed ID: 29635379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
    Wells AF; Edwards CJ; Kivitz AJ; Bird P; Guerette B; Delev N; Paris M; Teng L; Aelion JA
    Rheumatology (Oxford); 2022 Mar; 61(3):1035-1043. PubMed ID: 34100922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.
    Mease PJ
    Rheumatol Ther; 2014 Dec; 1(1):1-20. PubMed ID: 27747762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
    Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
    Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA;
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib.
    Dikranian A; Gold D; Bessette L; Nash P; Azevedo VF; Wang L; Woolcott J; Shapiro AB; Szumski A; Fleishaker D; Wollenhaupt J
    Rheumatol Ther; 2022 Apr; 9(2):411-433. PubMed ID: 34921355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
    J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED
    Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis.
    Taylor PC; van der Heijde D; Landewé R; McCue S; Cheng S; Boonen A
    J Rheumatol; 2021 Aug; 48(8):1259-1267. PubMed ID: 33589554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.